NCT01086436已完成1 期
Reactogenicity and Safety of a Single Dose of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563) in Healthy Children
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Occurrence of each solicited symptom
研究概览
简要总结
The purpose of this study is to assess the safety of Rotarix ™ when administered in healthy children aged 2 to 6 years in China.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 2 Years 至 6 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects who the investigator believes that their parents/guardians (Legally acceptable representative) can and will comply with the requirements of the protocol should be enrolled in the study.
- •A male or female subject of Chinese origin, between, and including, 2 and 6 years of age at the time of vaccination.
- •Written informed consent obtained from the parent or legally acceptable representative of the subject.
- •Healthy subjects as established by medical history and clinical examination before entering into the study.
排除标准
- •Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the study vaccine, or planned use during the study period.
- •Chronic administration of immunosuppressants or other immune-modifying drugs six months prior to the vaccine dose.
- •Planned administration/administration of a vaccine not foreseen by the study protocol within 14 days of the Human Rotavirus vaccine or placebo with the exception of the routine childhood vaccines. Routine childhood vaccines must not be administered on the same day as the Human Rotavirus vaccine or placebo.
- •Administration of immunoglobulins and/or any blood products since birth within three months preceding the study vaccine or planned administration during the study period.
- •Major congenital defects or serious chronic illness.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- •History of Intusussception or any chronic gastrointestinal disease that would predispose for Intusussception including any uncorrected congenital malformation of the gastrointestinal tract.
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- •Acute disease at the time of enrolment.
- •Gastroenteritis within 7 days preceding the study vaccine or placebo administration.
- •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product..
- •Child in care.
结局指标
主要结局
Occurrence of each solicited symptom
时间窗: Within the 8-day (Day 0 - Day 7) follow-up period after the vaccine dose.
次要结局
- Occurrence of unsolicited adverse events(Within the 31 days (Day 0 - Day 30) after the vaccine dose.)
- Occurrence of serious adverse events(Throughout the study period following the vaccine dose.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Evaluate the Reactogenicity and Safety of Rotarix™ in Chinese AdultsInfections, RotavirusNCT01162590GlaxoSmithKline52
已完成
4 期
Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.Infections, RotavirusNCT01198769GlaxoSmithKline15
已完成
1 期
Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy AdultsPneumococcal DiseaseNCT01767402GlaxoSmithKline150
已完成
1 期
Study to Assess the Safety of GSK Biologicals' Liquid Human Rotavirus Vaccine in Healthy InfantsInfections, RotavirusNCT01107587GlaxoSmithKline50
已完成
不适用
Intussusception Surveillance After Rotarix Introduction in MexicoIntussusception (IS)Rotavirus VaccinesNCT00595205GlaxoSmithKline786